Table 3.
Clinical outcomes amongst people with NAFLD cirrhosis without prior decompensations.
| Outcomes | Pre-pandemic | Pandemic | p value |
|---|---|---|---|
| First liver-related event, n (%) | 20/271 (7.4) | 28/247 (11.3) | 0.12 |
| Type of first LRE, n (% to all LRE) | |||
| Ascites | 10 (50.0) | 17 (60.7) | |
| Hepatic encephalopathy | 4 (20.0) | 5 (17.8) | |
| Upper gastrointestinal bleeding | 1 (5.0) | 0 (0) | |
| HCC | 5 (25.0) | 6 (21.4) | |
| CV events, n (%) | 6/271 (2.2) | 3/262 (1.1) | 0.24 |
| Type of CV event, n (% to all CV) | |||
| Cerebrovascular | 1 (16.6) | 1 (33.3) | |
| Ischemic heart disease | 3 (50.0) | 1 (33.3) | |
| Others | 2 (33.3) | 1 (33.3) | |
| Mortality, n (%) | 9/271 (3.3) | 16/262 (6.1) | 0.12 |
| Cause of death, n (% to all death) | |||
| Liver-related | 5 (55.5) | 1 (6.2) | |
| CV | 0 | 1 (6.2) | |
| Extrahepatic cancer | 1 (11.1) | 2 (12.5) | |
| COVID-19 | 0 | 9 (56.2) | |
| Other | 3 (33.3) | 3 (18.7) | |
| Composite endpoint (any clinical outcome), n (%) | 27/271 (9.9) | 44/247 (17.8) | 0.009 |
All comparisons were performed using the test on the equality of proportions. A p <0.05 was considered statistically significant.
CV, cardiovascular; HCC, hepatocellular carcinoma; LRE, liver-related event.